Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

Shanghai Stock Exchange 603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Price to Book Ratio (P/B) on January 14, 2025: 3.25

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Price to Book Ratio (P/B) is 3.25 on January 14, 2025, a -16.89% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd 52-week high Price to Book Ratio (P/B) is 4.34 on October 18, 2024, which is 33.74% above the current Price to Book Ratio (P/B).
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd 52-week low Price to Book Ratio (P/B) is 2.97 on August 27, 2024, which is -8.68% below the current Price to Book Ratio (P/B).
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd average Price to Book Ratio (P/B) for the last 52 weeks is 3.57.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

CEO	Ms. Wu Guiping
IPO Date	July 19, 2017
Location	China
Headquarters	1/16 Nanjing Jiangbei New
Employees	1,451
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd manufactures and sells heparin sodium and low molecular weight heparin products for pharmaceutical companies in the People's Republic of China. It offers enoxaparin sodium, dalteparin sodium, and naqu heparin calcium injections. The company also exports its products primarily to the European and American countries. The company was founded in 2000 and is based in Nanjing, the People's Republic of China.

Key trends

Past 5 years